Pilar received her PhD in 2017 at the Complutense University of Madrid, where she studied immune cell dysfunction and hyperactivation in HIV / HCV coinfected patients, as well as the in vitro and in vivo activity of nanoparticles against HIV - 1 and HSV - 2 infections to prevent their transmission in humans as
a topical microbicide.